Navigation Links
OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial
Date:9/19/2011

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 19, 2011 /PRNewswire/ -- Today OncoGenex (NASDAQ: OGXI) announced that the company has successfully completed an amendment to the approved SPA with the U.S. Food and Drug Administration (FDA) to expand the inclusion criteria for the Prostate Cancer SATURN Clinical Trial - a Phase III study testing whether their experimental drug custirsen, also known as OGX-011/TV-1011, can improve quality of life by reducing cancer pain for more than 12 weeks in men with metastatic castrate-resistant prostate cancer (mCRPC). As part of the approved amendment to the protocol and the SPA, patients may now receive either docetaxel re-treatment or cabazitaxel as second-line taxane chemotherapy. The study design remains the same; all patients must have stable pain at study entry and will be randomized to receive custirsen or placebo in conjunction with taxane chemotherapy.

"Until recently, docetaxel was the only standard of care for chemotherapy treatment of mCRPC with a demonstrated survival benefit," said Dr. Tomasz Beer, the study's principal investigator in the United States.  "With the recent approval of cabazitaxel for mCRPC treatment after docetaxel, men have a new option that extends survival.  In an effort to improve the palliative benefits of this new treatment, we are evaluating custirsen with cabazitaxel for pain palliation. Pain palliation in patients treated with cabazitaxel was reported at 9.2% and pain is one of the most common and devastating consequences of very advanced prostate cancer."

Custirsen is an experimental drug that is designed to block the production of a protein that is associated with treatment resistance in many cancers. In Phase II trials, custirsen combined with docetaxel as either first-line or second-line chemotherapy showed a 6.9 month improvement in overall survival over doc
'/>"/>

SOURCE OncoGenex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
2. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
3. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
4. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
5. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  As cannabis prohibition ends one state at a time, more cannabis entrepreneurs are coming up with brilliant ... and the primary reason is lack of funding. ... ... ... ...
(Date:5/5/2015)... 5, 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... months ended March 31, 2015 and reaffirmed its revenue, ... 2015. First Quarter 2015 Highlights Include: ... of 72% as compared to $10.9 million for the ... non-GAAP EBITDA of $11.5 million, an increase of 170% as ...
(Date:5/5/2015)... , May 5, 2015  Abaxis, Inc. (NasdaqGS: ABAX ... announced today that Clint Severson , chairman and chief ... Lynch 2015 Health Care Conference on Tuesday, May 12, 2015 ... the Encore at the Wynn in Las Vegas, ... worldwide developer, manufacturer and marketer of portable blood analysis systems ...
Breaking Medicine Technology:Top Ten Ways Cannabis Startups are Getting Funded 2Top Ten Ways Cannabis Startups are Getting Funded 3Top Ten Ways Cannabis Startups are Getting Funded 4ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 2ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 3ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 4ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 5ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 6ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 7ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 8ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 9
... CSL Behring today announced that the U.S. Food and ... License Application (BLA) for a human 4-factor prothrombin complex concentrate ... warfarin) in patients with acute major bleeding. If approved by ... first agent of its kind available in the United States. ...
... 29, 2012 Specialty Silicone Fabricators (SSF), a ... device community, inaugurated its state-of-the-art 102,000 square-foot facility ... efficiency, the facility joins all Paso Robles departments, ... facilities in Tustin, Calif. and Elk Rapids, Mich. ...
Cached Medicine Technology:CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy 2CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy 3Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles 2
(Date:5/5/2015)... May 05, 2015 HealthSlide, ... innovative interoperability solutions for hospitals nationwide, has announced ... calculator. Hospital CIOs and CTOs can access the ... calculator shows both initial and ongoing savings of ... , “Our nation’s hospitals pay an average of ...
(Date:5/5/2015)... After record-breaking sales of Extend Nutrition’s ... Cookies & Cream flavor at stores nationwide this month. ... raised the bar for nutritional snacks. The brand ... nutritional profile, backed by international patents and clinical studies. ... additional new products and expand retail availability throughout 2015. ...
(Date:5/5/2015)... Grants Pass, OR (PRWEB) May 05, 2015 ... winter dry eye seasons. Turns out, the worst dry eye ... atmospheric pollen count spikes in most of the United States. ... is autumn. Fresh water advocate Sharon Kleyne, host of the ... spring dry eye on her radio show of May 11, ...
(Date:5/5/2015)... 2015 B. E. Smith, the only ... has been retained to recruit a new administrator ... top executive search firm in the healthcare industry, B. ... executives into organizations. , Shodair Children’s Hospital is the ... to offer both acute and residential inpatient services, as ...
(Date:5/5/2015)... MO (PRWEB) May 05, 2015 The ... 2015 from 5:00 to 8:00 pm at the Rochester Marriott, ... hospitals, clinics and groups with career opportunities will be attending ... will enjoy free hors d’oeuvres and raffle prize drawings. , ... says, “Rochester is an ideal location to hold a career ...
Breaking Medicine News(10 mins):Health News:HealthSlide Launches ROI Cost Calculator 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 2Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 3Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 3
... ... of Novasys Medical Inc., will receive the Adaptive Business Leaders Organization (ABL)’s 2010 “Leadership ... HealthcareSM Awards Event, on April 28, in Newport Beach, California. , ... Santa Ana, CA (PRWEB) March 2, ...
... ... ... ... ...
... ... ... , ... , , ...
... providing insight into how estrogen fuels many breast cancers, and ... Researchers found that estrogen inhibits a protein called MLK3 ... growth of cancer cells and resistance to chemotherapy. Researchers ... the findings in the journal Cancer Research . ...
... ARBOR, Mich.---Only 68 percent of corporate executives took their ... new study shows. Overall, the executives who ... to meet their cholesterol goals. The study finding also ... factor in medication adherence. University of Michigan ...
... who join a sorority* are more likely to judge ... self-objectification) and display higher levels of bulimic attitudes and ... the sorority,s recruitment process. Over time, those women who ... shame. These findings, part of Ashley Marie Rolnik,s senior ...
Cached Medicine News:Health News:Novasys Medical's Debra Reisenthel Named ABL's 2010 “Leadership in Innovation” Awardee 2Health News:Novasys Medical's Debra Reisenthel Named ABL's 2010 “Leadership in Innovation” Awardee 3Health News:President Obama Gets Virtual Colonoscopy (CT Colonography) But Medicare Denies CTC Coverage to Seniors 2Health News:President Obama Gets Virtual Colonoscopy (CT Colonography) But Medicare Denies CTC Coverage to Seniors 3Health News:President Obama Gets Virtual Colonoscopy (CT Colonography) But Medicare Denies CTC Coverage to Seniors 4Health News:President Obama Gets Virtual Colonoscopy (CT Colonography) But Medicare Denies CTC Coverage to Seniors 5Health News:President Obama Gets Virtual Colonoscopy (CT Colonography) But Medicare Denies CTC Coverage to Seniors 6Health News:Nemours Data Show Childhood Overweight and Obesity Leveling Off in Delaware 2Health News:Nemours Data Show Childhood Overweight and Obesity Leveling Off in Delaware 3Health News:Nemours Data Show Childhood Overweight and Obesity Leveling Off in Delaware 4Health News:Nemours Data Show Childhood Overweight and Obesity Leveling Off in Delaware 5Health News:Even the boss doesn't follow the doctor's orders 2Health News:Only the beautiful need apply 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: